Puru Rattan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Puru Rattan has a total of 118 co-authors. Here are the top co-authors by number of shared publications:
- Douglas Alano Simonetto
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA
12 shared publications - Patrick S. Kamath
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA
10 shared publications - Vijay H. Shah
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA
8 shared publications - Ryan J. Lennon
R.J. Lennon, MS, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA
6 shared publications - Joseph C. Ahn
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA
5 shared publications - Peter A. Noseworthy
Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA
4 shared publications
Latest Publications
- Open Access
- 10 February 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (3) , 1160
Author Correction: Detection of undiagnosed liver cirrhosis via AI-enabled electrocardiogram: a pragmatic, cluster-randomized clinical trial
- 10 February 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (3) , 1160
Open AccessAuthor Correction: Detection of undiagnosed liver cirrhosis via AI-enabled electrocardiogram: a pragmatic, cluster-randomized clinical trial
- Open Access
- 1 January 2026
- Published by Wiley in Canadian Journal of Gastroenterology and Hepatology
- Vol. 2026 (1) , 5532035
Beyond the INR: Thromboelastography Carries Prognostic Information in Critically Ill Patients With Cirrhosis
Background: In patients with cirrhosis, prolonged international normalized ratio (INR) is primarily driven by liver synthetic dysfunction. Thromboelastography more accurately reflects coagulability and can also predict short‐term mortality. Nevertheless, INR is used to define coagulation failure in the European Foundation for the Study of Chronic Liver Failure criteria for acute‐on‐chronic liver failure (ACLF). Aim: To evaluate the association between TEG parameters and mortality in critically ill patients with cirrhosis and to justify future investigation into TEG as a prognostic tool in ACLF. Methods: We performed a retrospective study of 52 patients with cirrhosis admitted to the intensive care unit (ICU) who had TEG performed during their ICU admission prior to the administration of any blood products. We assessed the association between TEG parameters and 28‐day mortality. Results: Patients who did not survive beyond 28 days generally had more hypocoagulable TEG parameters (R time: 10.0 vs. 7.6, p = 0.03; K time: 3.4 vs. 2.2, p = 0.003; alpha angle: 53.1 vs. 63.5, p = 0.002; MA: 49.2 vs. 60.2, p = 0.001). Although global assessment of TEG demonstrated a state of rebalanced hemostasis among critically ill patients with cirrhosis, patients meeting diagnostic criteria for ACLF tended to have more hypocoagulable TEG parameters as compared to those who did not (coagulation index: 0.2 vs. 2.0, p = 0.004). As proof of concept, MA was incorporated into the definition of ACLF to replace INR as a marker of coagulation failure (TEG‐ACLF). The area under the curve (AUC) for TEG‐ACLF was 0.83 (0.72–0.95) compared to 0.8 (0.68–0.92) for the current ACLF‐CLIF grading, with 9.6% (5/52) of patients being reclassified into a different ACLF grade. Conclusion: Hypocoagulable TEG parameters are associated with increased 28‐day mortality in critically ill patients with cirrhosis, and incorporation of TEG parameters into a modified definition for ACLF may result in improved prediction of short‐term mortality.
- 1 January 2026
- Published by Wiley in Canadian Journal of Gastroenterology and Hepatology
- Vol. 2026 (1) , 5532035
Open AccessBeyond the INR: Thromboelastography Carries Prognostic Information in Critically Ill Patients With Cirrhosis
Background: In patients with cirrhosis, prolonged international normalized ratio (INR) is primarily driven by liver synthetic dysfunction. Thromboelastography more accurately reflects coagulability and can also predict short‐term mortality. Nevertheless, INR is used to define coagulation failure in the European Foundation for the Study of Chronic Liver Failure criteria for acute‐on‐chronic liver failure (ACLF). Aim: To evaluate the association between TEG parameters and mortality in critically ill patients with cirrhosis and to justify future investigation into TEG as a prognostic tool in ACLF. Methods: We performed a retrospective study of 52 patients with cirrhosis admitted to the intensive care unit (ICU) who had TEG performed during their ICU admission prior to the administration of any blood products. We assessed the association between TEG parameters and 28‐day mortality. Results: Patients who did not survive beyond 28 days generally had more hypocoagulable TEG parameters (R time: 10.0 vs. 7.6, p = 0.03; K time: 3.4 vs. 2.2, p = 0.003; alpha angle: 53.1 vs. 63.5, p = 0.002; MA: 49.2 vs. 60.2, p = 0.001). Although global assessment of TEG demonstrated a state of rebalanced hemostasis among critically ill patients with cirrhosis, patients meeting diagnostic criteria for ACLF tended to have more hypocoagulable TEG parameters as compared to those who did not (coagulation index: 0.2 vs. 2.0, p = 0.004). As proof of concept, MA was incorporated into the definition of ACLF to replace INR as a marker of coagulation failure (TEG‐ACLF). The area under the curve (AUC) for TEG‐ACLF was 0.83 (0.72–0.95) compared to 0.8 (0.68–0.92) for the current ACLF‐CLIF grading, with 9.6% (5/52) of patients being reclassified into a different ACLF grade. Conclusion: Hypocoagulable TEG parameters are associated with increased 28‐day mortality in critically ill patients with cirrhosis, and incorporation of TEG parameters into a modified definition for ACLF may result in improved prediction of short‐term mortality.
- 17 December 2025
- Published by Springer Nature in Nature Medicine
- Vol. 32 (1) , 160-167
Detection of undiagnosed liver cirrhosis via AI-enabled electrocardiogram: a pragmatic, cluster-randomized clinical trial
Advanced chronic liver disease (CLD) affects 2–5% of the general population, and accessible screening tools are needed in primary care. Here we conducted a pragmatic trial to assess whether an electrocardiogram (ECG)-based machine learning (ECG-ML) model enables early detection of advanced CLD. In this trial, 98 primary care teams were cluster randomized to intervention (access to ECG-ML results; 123 clinicians) or usual care (122 clinicians). Clinicians in the intervention arm were notified of a positive ECG-ML result, indicating higher risk of advanced CLD. The primary endpoint was new diagnosis of CLD with advanced fibrosis within 180 days of ECG, confirmed by sequential liver disease assessments. A total of 15,596 adults underwent 12-lead ECGs as part of routine care and met inclusion criteria (N = 8,034 intervention and N = 7,562 control). The intervention significantly increased new diagnoses of advanced CLD in the overall cohort (1.0% versus 0.5% in the control arm; odds ratio (OR) 2.09, 95% confidence interval (CI) 1.22–3.55, P = 0.007). Among ECG-ML-positive patients, advanced CLD was more frequent in the intervention arm (4.4% versus 1.1%; OR 4.37, 95% CI 1.94–9.88, P < 0.001). The intervention also increased the detection of any fibrosis (secondary endpoint) in the overall cohort (1.7% versus 0.5%; OR 3.17, 95% CI 1.86–5.40, P < 0.001) and among ECG-ML-positive patients (8.4% versus 1.1%; OR 8.03, 95% CI 3.50–18.4, P < 0.001). The diagnostic yield below epidemiological estimates probably reflects variable clinician adherence to artificial intelligence-driven recommendations. These results demonstrate that an ECG-based machine learning model, followed by targeted testing based on risk factors, may aid case finding of advanced CLD in routine primary care. ClinicalTrials.gov registration: NCT05782283.
- 17 December 2025
- Published by Springer Nature in Nature Medicine
- Vol. 32 (1) , 160-167
Detection of undiagnosed liver cirrhosis via AI-enabled electrocardiogram: a pragmatic, cluster-randomized clinical trial
Advanced chronic liver disease (CLD) affects 2–5% of the general population, and accessible screening tools are needed in primary care. Here we conducted a pragmatic trial to assess whether an electrocardiogram (ECG)-based machine learning (ECG-ML) model enables early detection of advanced CLD. In this trial, 98 primary care teams were cluster randomized to intervention (access to ECG-ML results; 123 clinicians) or usual care (122 clinicians). Clinicians in the intervention arm were notified of a positive ECG-ML result, indicating higher risk of advanced CLD. The primary endpoint was new diagnosis of CLD with advanced fibrosis within 180 days of ECG, confirmed by sequential liver disease assessments. A total of 15,596 adults underwent 12-lead ECGs as part of routine care and met inclusion criteria (N = 8,034 intervention and N = 7,562 control). The intervention significantly increased new diagnoses of advanced CLD in the overall cohort (1.0% versus 0.5% in the control arm; odds ratio (OR) 2.09, 95% confidence interval (CI) 1.22–3.55, P = 0.007). Among ECG-ML-positive patients, advanced CLD was more frequent in the intervention arm (4.4% versus 1.1%; OR 4.37, 95% CI 1.94–9.88, P < 0.001). The intervention also increased the detection of any fibrosis (secondary endpoint) in the overall cohort (1.7% versus 0.5%; OR 3.17, 95% CI 1.86–5.40, P < 0.001) and among ECG-ML-positive patients (8.4% versus 1.1%; OR 8.03, 95% CI 3.50–18.4, P < 0.001). The diagnostic yield below epidemiological estimates probably reflects variable clinician adherence to artificial intelligence-driven recommendations. These results demonstrate that an ECG-based machine learning model, followed by targeted testing based on risk factors, may aid case finding of advanced CLD in routine primary care. ClinicalTrials.gov registration: NCT05782283.
- 23 September 2025
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 32 (4) , 582-591
HCV NAT+ consent improves liver transplant and waitlist mortality in patients listed for HCC MELD exceptions
There is a significant supply–demand mismatch in liver transplantation. Organs from HCV nucleic acid amplification test (NAT)+ donors have reduced time to transplant and waitlist mortality; however, the impact of HCV listing on waitlist outcomes is unknown in patients listed with HCC MELD exceptions. We conducted a retrospective cohort study using US transplant registry data. Patients listed for a single-organ liver transplant from January 2016 to October 2023 with active HCC MELD exceptions were included and categorized by HCV NAT+ listing status. Trends in NAT+ listing were explored across time and centers. Adjusted associations between NAT+ listing and transplantation or waitlist death were evaluated using competing risk models. Of the 15,852 patients listed for HCC MELD exceptions, 4954 (31.3%) were listed for HCV NAT+ organs, while 10,898 (68.7%) were not. The proportion of NAT+ listed patients increased from 21% (2016) to 56% (2023). There was substantial center-level variation in the proportion of HCV NAT+ listed patients. HCV NAT+ listing was associated with increased subhazard of transplantation (sHR 1.46, 95% CI 1.33–1.61, p p =0.038). The effect of HCV NAT+ listing on transplant likelihood was amplified after accounting for time-updated receipt of exception points at 6 months (csHR 11.4, 95% CI 9.15–14.1, p <0.001). HCV NAT+ listing has increased in HCC MELD exception patients, and listing is associated with increased transplantation and reduced mortality. Given substantial center-level variability in NAT+ listing, standardized efforts are needed to improve patient education and access to HCV NAT+ organs.
- 23 September 2025
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 32 (4) , 582-591
HCV NAT+ consent improves liver transplant and waitlist mortality in patients listed for HCC MELD exceptions
There is a significant supply–demand mismatch in liver transplantation. Organs from HCV nucleic acid amplification test (NAT)+ donors have reduced time to transplant and waitlist mortality; however, the impact of HCV listing on waitlist outcomes is unknown in patients listed with HCC MELD exceptions. We conducted a retrospective cohort study using US transplant registry data. Patients listed for a single-organ liver transplant from January 2016 to October 2023 with active HCC MELD exceptions were included and categorized by HCV NAT+ listing status. Trends in NAT+ listing were explored across time and centers. Adjusted associations between NAT+ listing and transplantation or waitlist death were evaluated using competing risk models. Of the 15,852 patients listed for HCC MELD exceptions, 4954 (31.3%) were listed for HCV NAT+ organs, while 10,898 (68.7%) were not. The proportion of NAT+ listed patients increased from 21% (2016) to 56% (2023). There was substantial center-level variation in the proportion of HCV NAT+ listed patients. HCV NAT+ listing was associated with increased subhazard of transplantation (sHR 1.46, 95% CI 1.33–1.61, p p =0.038). The effect of HCV NAT+ listing on transplant likelihood was amplified after accounting for time-updated receipt of exception points at 6 months (csHR 11.4, 95% CI 9.15–14.1, p <0.001). HCV NAT+ listing has increased in HCC MELD exception patients, and listing is associated with increased transplantation and reduced mortality. Given substantial center-level variability in NAT+ listing, standardized efforts are needed to improve patient education and access to HCV NAT+ organs.
- 27 March 2025
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 120 (10) , 2452-2456
Training and Performance of an Electrocardiogram-Enabled Machine Learning Model for Detection of Advanced Chronic Liver Disease
INTRODUCTION: Building on prior results, we hypothesized that an electrocardiogram (ECG)-enabled machine learning (ML) model could be used to detect advanced chronic liver disease (CLD). METHODS: A cohort with CLD and 12-lead ECGs was matched with controls from electronic health records. A ML model was trained as a binary classifier. RESULTS: There are 12,930 patients with CLD and 64,577 controls in the cohort. The model's discriminative ability to classify CLD showed an area under the receiver-operating characteristic curve 0.858 (95% confidence interval: 0.850–0.866), and at the chosen threshold, CLD ECGs had 12 times higher odds of being classified as CLD (diagnostic odds ratio 12.33, 95% confidence interval: 11.16–13.63). DISCUSSION: An ECG-enabled ML model affords great promise in identifying advanced CLD in low resource areas.
- 27 March 2025
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 120 (10) , 2452-2456
Training and Performance of an Electrocardiogram-Enabled Machine Learning Model for Detection of Advanced Chronic Liver Disease
INTRODUCTION: Building on prior results, we hypothesized that an electrocardiogram (ECG)-enabled machine learning (ML) model could be used to detect advanced chronic liver disease (CLD). METHODS: A cohort with CLD and 12-lead ECGs was matched with controls from electronic health records. A ML model was trained as a binary classifier. RESULTS: There are 12,930 patients with CLD and 64,577 controls in the cohort. The model's discriminative ability to classify CLD showed an area under the receiver-operating characteristic curve 0.858 (95% confidence interval: 0.850–0.866), and at the chosen threshold, CLD ECGs had 12 times higher odds of being classified as CLD (diagnostic odds ratio 12.33, 95% confidence interval: 11.16–13.63). DISCUSSION: An ECG-enabled ML model affords great promise in identifying advanced CLD in low resource areas.
- Open Access
- 19 February 2025
- Published by Elsevier in JHEP Reports
- Vol. 7 (5) , 101356
AI-Cirrhosis-ECG (ACE) score for predicting decompensation and liver outcomes
- 19 February 2025
- Published by Elsevier in JHEP Reports
- Vol. 7 (5) , 101356
Open AccessAI-Cirrhosis-ECG (ACE) score for predicting decompensation and liver outcomes
- Open Access
- 24 October 2024
- Published by Elsevier in American Journal of Transplantation
- Vol. 25 (4) , 793-803
Trends in candidate hepatitis C virus nucleic acid amplification test (NAT)+ listing and associated impacts on liver transplantation waitlist outcomes
- 24 October 2024
- Published by Elsevier in American Journal of Transplantation
- Vol. 25 (4) , 793-803
Open AccessTrends in candidate hepatitis C virus nucleic acid amplification test (NAT)+ listing and associated impacts on liver transplantation waitlist outcomes
- 24 October 2024
- Published by Elsevier in Journal of Hepatology
- Vol. 82 (4) , e199-e200
Underrecognized association of porto-sinusoidal vascular disorder and telomere biology disorders
- 24 October 2024
- Published by Elsevier in Journal of Hepatology
- Vol. 82 (4) , e199-e200
Underrecognized association of porto-sinusoidal vascular disorder and telomere biology disorders
- Open Access
- 22 July 2024
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 8 (8)
Design, implementation, and impact of a cirrhosis-specific remote patient monitoring program
Background: Remote patient monitoring (RPM) is an emerging focus in health care, and specialized programs may reduce medical costs, supplement in-office visits, and improve patient satisfaction. In this study, we describe the development, feasibility, and early outcomes of an RPM program for patients with decompensated cirrhosis. Methods: Forty-six patients were offered enrollment at the time of hospital discharge in the cirrhosis RPM program (CiRPM), of which 41 completed at least 30 days of monitoring. Participants were mailed remote monitoring equipment and a tablet to be used for patient-reported outcomes. Alerts were continuously monitored by virtual nursing staff who could perform targeted interventions. A cohort of historical controls (n = 74) was created for comparison using inverse probability of treatment weighting. Results: Patients were enrolled in the program for a mean of 83.9 days, with 28 (68%) completing the full 90-day program. Participants uploaded vital signs and responded to symptom-based questionnaires on 93% of the monitored days. On end-of-program surveys, over 75% of patients expressed satisfaction with the program. Gender, age, and MELD-Na were similar between CiRPM and weighted control groups. The 90-day readmission rate was 34% in CiRPM and 47% in weighted controls. In the CiRPM group, 12% of subjects had 2 or more admissions, compared to 37% in the weighted control group. Conclusion: This study demonstrates the feasibility of a cirrhosis-specific RPM program. Overall, patient satisfaction and utilization of the CiRPM was high. Future studies are needed to confirm the impact of RPM on the reduction of hospital readmissions in decompensated cirrhosis. Export
- 22 July 2024
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 8 (8)
Open AccessDesign, implementation, and impact of a cirrhosis-specific remote patient monitoring program
Background: Remote patient monitoring (RPM) is an emerging focus in health care, and specialized programs may reduce medical costs, supplement in-office visits, and improve patient satisfaction. In this study, we describe the development, feasibility, and early outcomes of an RPM program for patients with decompensated cirrhosis. Methods: Forty-six patients were offered enrollment at the time of hospital discharge in the cirrhosis RPM program (CiRPM), of which 41 completed at least 30 days of monitoring. Participants were mailed remote monitoring equipment and a tablet to be used for patient-reported outcomes. Alerts were continuously monitored by virtual nursing staff who could perform targeted interventions. A cohort of historical controls (n = 74) was created for comparison using inverse probability of treatment weighting. Results: Patients were enrolled in the program for a mean of 83.9 days, with 28 (68%) completing the full 90-day program. Participants uploaded vital signs and responded to symptom-based questionnaires on 93% of the monitored days. On end-of-program surveys, over 75% of patients expressed satisfaction with the program. Gender, age, and MELD-Na were similar between CiRPM and weighted control groups. The 90-day readmission rate was 34% in CiRPM and 47% in weighted controls. In the CiRPM group, 12% of subjects had 2 or more admissions, compared to 37% in the weighted control group. Conclusion: This study demonstrates the feasibility of a cirrhosis-specific RPM program. Overall, patient satisfaction and utilization of the CiRPM was high. Future studies are needed to confirm the impact of RPM on the reduction of hospital readmissions in decompensated cirrhosis. Export
- Open Access
- 1 January 2024
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 8 (1)
Serum lactate and mean arterial pressure thresholds in patients with cirrhosis and septic shock
Background: The Sepsis-3 guidelines have incorporated serum lactate levels of >2 mmol/L in septic shock definition to account for higher observed mortality. Further evidence is needed to support this threshold in cirrhosis, as well as target mean arterial pressure (MAP) during resuscitation. Methods: This observational cohort study investigated the association between initial serum lactate and resuscitation MAP levels on in-hospital mortality in patients with and without cirrhosis. Patients admitted to the intensive care unit for the treatment of septic shock between 2006 and 2021 in a quaternary academic center were included. Patients with cirrhosis documented on imaging and International Classification of Disease codes (n=595) were compared to patients without cirrhosis (n=575). The association of intensive care unit admission lactate levels and median 2-hour MAP with in-hospital mortality and the need for continuous renal replacement therapy was assessed. The association between median 24-hour MAP and in-hospital mortality was analyzed post hoc. Results: Within the cirrhosis group, admission lactate levels of 2–4 and >4 mmol/L were associated with increased in-hospital mortality compared to lactate 4 mmol/L (aOR: 1.32, CI: 0.77–2.27 and aOR: 2.25, CI: 1.40–3.67) and median 24-hour MAP 60–65 and 2 mmol/L in the definition of septic shock, as well as a target MAP of >65 mm Hg during resuscitation in patients with cirrhosis. Export
- 1 January 2024
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 8 (1)
Open AccessSerum lactate and mean arterial pressure thresholds in patients with cirrhosis and septic shock
Background: The Sepsis-3 guidelines have incorporated serum lactate levels of >2 mmol/L in septic shock definition to account for higher observed mortality. Further evidence is needed to support this threshold in cirrhosis, as well as target mean arterial pressure (MAP) during resuscitation. Methods: This observational cohort study investigated the association between initial serum lactate and resuscitation MAP levels on in-hospital mortality in patients with and without cirrhosis. Patients admitted to the intensive care unit for the treatment of septic shock between 2006 and 2021 in a quaternary academic center were included. Patients with cirrhosis documented on imaging and International Classification of Disease codes (n=595) were compared to patients without cirrhosis (n=575). The association of intensive care unit admission lactate levels and median 2-hour MAP with in-hospital mortality and the need for continuous renal replacement therapy was assessed. The association between median 24-hour MAP and in-hospital mortality was analyzed post hoc. Results: Within the cirrhosis group, admission lactate levels of 2–4 and >4 mmol/L were associated with increased in-hospital mortality compared to lactate 4 mmol/L (aOR: 1.32, CI: 0.77–2.27 and aOR: 2.25, CI: 1.40–3.67) and median 24-hour MAP 60–65 and 2 mmol/L in the definition of septic shock, as well as a target MAP of >65 mm Hg during resuscitation in patients with cirrhosis. Export